Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
PaperCitations, authors & open-access status
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,664 citations, 2019 year and closed oa status.
1,664
Citations
2019
Year
closed
OA Status